Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) EBIT Margin (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed EBIT Margin for 8 consecutive years, with 435.06% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin fell 28838.0% year-over-year to 435.06%, compared with a TTM value of 92.96% through Dec 2025, down 3015.0%, and an annual FY2025 reading of 92.96%, down 3015.0% over the prior year.
  • EBIT Margin was 435.06% for Q4 2025 at Arcturus Therapeutics Holdings, down from 96.26% in the prior quarter.
  • Across five years, EBIT Margin topped out at 75.77% in Q4 2022 and bottomed at 2711.14% in Q1 2021.
  • Average EBIT Margin over 5 years is 551.52%, with a median of 88.9% recorded in 2025.
  • The sharpest move saw EBIT Margin crashed -235355bps in 2021, then soared 260313bps in 2022.
  • Year by year, EBIT Margin stood at 649.72% in 2021, then soared by 112bps to 75.77% in 2022, then tumbled by -178bps to 59.22% in 2023, then tumbled by -148bps to 146.68% in 2024, then crashed by -197bps to 435.06% in 2025.
  • Business Quant data shows EBIT Margin for ARCT at 435.06% in Q4 2025, 96.26% in Q3 2025, and 41.04% in Q2 2025.